Infliximab use in Crohn's disease: Impact on health care resources in the UK

Derek P. Jewell, Jack Satsangi, Alan Lobo, Christopher Probert, Alastair Forbes, Subrata Ghosh, Jon Shaffer, Markus Frenz, Hazel Drummond, Gill Troy, Sue Turner, Lisa Younge, Lyn Evans, Mark Moosa, Barry Rodgers-Gray, Scot Buchan

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)


To quantify the impact of infliximab therapy on health care resource utilization in the UK.
Original languageEnglish
Pages (from-to)1047-52
Number of pages6
JournalEuropean Journal of Gastroenterology & Hepatology
Issue number10
Publication statusPublished - Oct 2005


  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Cost-Benefit Analysis
  • Crohn Disease
  • Drug Costs
  • Epidemiologic Methods
  • Female
  • Great Britain
  • Health Care Costs
  • Health Resources
  • Health Services Research
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha

Cite this